Effect of 4-hydroxyphenylretinamide on human cervical epithelial and cancer cell lines

Journal of the Society for Gynecologic Investigation

Volumn 10, Issue 1, 2003, Pages 41-48

  Zou, Changping ^a,b,c   Vlastos, Anne Thérèse ^a,b,c   Yang, Li ^a,b,c   Wang, Jian ^a,b,c   Brewer, Molly ^a,b,c   Follen, Michele ^a,b,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

4 hydroxyphenylretinamide; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus; Squamous intraepithelial lesions

Indexed keywords

FENRETINIDE; RETINOIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL CULTURE; CELL IMMORTALIZATION; CELL LINE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LABORATORY; MONOLAYER CULTURE; PRIORITY JOURNAL; SOLID; STATISTICAL SIGNIFICANCE; TIME; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; WART VIRUS;

CELL DIVISION; CELL LINE, TRANSFORMED; CERVIX UTERI; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FEMALE; FENRETINIDE; HUMANS; KINETICS; PAPILLOMAVIRIDAE; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VITAMIN A;

EID: 0037221980     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(02)00183-1     Document Type: Article

References (73)

1. Richart R. A radioautographic analysis of cellular proliferation in dysplasia and carcinoma in situ of the uterine cervix. Am J Obstet Gynecol. 86:1963;925-930.
2. Follen M. A Clinical Trial Using 4-Hydroxyphenylretinamide for the Treatment of High-grade Squamous Intraepithelial Lesions of the Cervix: An Interim Analysis [dissertation]. Ann Arbor, Michigan: University of Michigan, 2000.
3. Meyskens F. Jr, Surwit E., Moon T., et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid A randomized trial . J Natl Cancer Inst. 86:1994;539-543.
4. Veronesi U., De Palo G., Costa A., Formelli F., Decensi A. Chemoprevention of breast cancer with fenretinide. IARC Sci Publ. 136:1996;87-94.
5. Moon R.C., Thompson H.J., Becci P.J., et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 39:1979;1339-1346.
6. Paulson J.D., Oldham J.W., Preston R.F., Newman D. Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide. Fundam Appl Toxicol. 5:1985;144-150.
7. Formelli F., Barua A.B., Olson J.A. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. FASEB J. 10:1996;1014-1024.
8. Boone C., Bacus J., Bacus J., Steele V., Kelloff G. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials. Proc Soc Exp Biol Med. 216:1997;151-165.
9. Kelloff G.J., Boone C.W., Crowell J.A., et al. New agents for cancer chemoprevention. J Cell Biochem. 26:(Suppl):1996;1-28.
10. Sabichi A.L., Lerner S.P., Grossman H.B., Lippman S.M. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol. 10:1998;479-484.
11. Oridate N., Suzuki S., Higuchi M., Mitchell M.F., Hong W.K., Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst. 89:1997;1191-1198.
12. Dmitrovsky E. N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis. J Natl Cancer Inst. 89:1997;1179-1181.
13. Oridate N., Lotan D., Mitchell M.F., Hong W.K., Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids Implications for chemoprevention . J Cell Biochem. 23:(Suppl):1995;80-86.
14. Lotan R., Trizna Z., Zou C., Lotan D., Mitchell M., Zou C. Additive inhibitory effects of retinoids and interferon-a on the growth of human cervical carcinoma cells Lack of association with HPV status or retinoid receptor expression . Int J Cancer. 8:1996;5-13.
15. Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 90:1998;597-605.
16. Supino R., Crosti M., Clerici M., et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer. 65:1996;491-497.
17. Pergolizzi R., Appierto V., Crosti M., et al. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int J Cancer. 81:1999;829-834.
18. Sun S.Y., Li W., Yue P., Lippman S.M., Hong W.K., Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res. 59:1999;2493-2498.
19. Zou C.P., Kurie J.M., Lotan D., Zou C.C., Hong W.K., Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 4:1998;1345-1355.
20. Kalemkerian G.P., Ou X. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol. 43:1999;145-150.
21. Eicher S.A., Lotan R. Differential effects of retinoic acid and N-(4-hydroxyphenyl)retinamide on head and neck squamous cell carcinoma cells. Laryngoscope. 106:1996;1471-1475.
22. Scher R.L., Saito W., Dodge R.K., Richtsmeier W.J., Fine R.L. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines. Otolaryngol Head Neck Surg. 118:1998;464-471.
23. Oridate N., Lotan D., Xu X.C., Hong W.K., Lotan R. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 2:1996;855-863.
24. Muller A., Nakagawa H., Rustgi A.K. Retinoic acid and N-(4-hydroxy-phenyl) retinamide suppress growth of esophageal squamous carcinoma cell lines. Cancer Lett. 113:1997;95-101.
25. Shen J.C., Wang T.T., Chang S., Hursting S.D. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis. Mol Carcinog. 24:1999;160-168.
26. Sun S.Y., Yue P., Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol. 55:1999;403-410.
27. Webber M.M., Bello-DeOcampo D., Quader S., Deocampo N.D., Metcalfe W.S., Sharp R.M. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis. 17:1999;255-263.
28. Roberson K.M., Penland S.N., Padilla G.M., et al. Fenretinide Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells . Cell Growth Differ. 8:1997;101-111.
29. Hsieh T.C., Wu J.M. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate. 33:1997;97-104.
30. Wang T.T., Phang J.M. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett. 107:1996;65-71.
31. Kazmi S.M., Plante R.K., Visconti V., Lau C.Y. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res. 56:1996;1056-1062.
32. Coradini D., Biffi A., Pellizzaro C., Pirronello E., Di Fronzo G. Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines. Tumour Biol. 18:1997;22-29.
33. Jinno H., Steiner M.G., Mehta R.G., Osborne M.P., Telang N.T. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide. Carcinogenesis. 20:1999;229-236.
34. Aliprandis E.T., Merritt G., Prada F., Rigas B., Kashfi K. Fenretinide inhibits phorbol ester-induced cyclooxygenase-2 expression in human colon adenocarcinoma cells. Biochem Soc Trans. 25:1997;45 7S.
35. Altieri P., Caridi G., Chiesa V., Ponzoni M., Ghiggeri G.M. N-(4-hydroxyphenyl) retinamide inhibits cystogenesis by polycystic epithelial cell lines in vitro. Life Sci. 64:1999;L259-S265.
36. Zou C., Wang L., Liebert M., Grossman H.B., Lotan R., Wei Q. Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines. Int J Oncol. 13:1998;1037-1041.
37. Rozzo C., Chiesa V., Caridi G., Pagnan G., Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. Int J Cancer. 70:1997;688-698.
38. Maurer B.J., Metelitsa L.S., Seeger R.C., Cabot M.C., Reynolds C.P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 91:1999;1138-1146.
39. Montaldo P.G., Pagnan G., Pastorino F., et al. N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. Int J Cancer. 81:1999;262-267.
40. Pagnan G., Montaldo P.G., Pastorino F., et al. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer. 81:1999;268-274.
41. DiPietrantonio A.M., Hsieh T.C., Olson S.C., Wu J.M. Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer. 78:1998;53-61.
42. Takahashi N., Sausville E.A., Breitman T.R. N-(4-hydroxyphenyl)retinamide (fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins. Clin Cancer Res. 1:1995;637-642.
43. Dipietrantonio A., Hsieh T.C., Wu J.M. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem Biophys Res Commun. 224:1996;837-842.
44. Chan L.N., Zhang S., Shao J., Waikel R., Thompson E.A., Chan T.S. N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leuk Lymphoma. 25:1997;271-280.
45. Springer L.N., Stewart B.W. N-(4-hydroxyphenyl)retinamide-induced death in human lymphoblastoid cells 50 kb DNA breakage as a means of distinguishing apoptosis from necrosis . Cancer Lett. 128:1998;189-196.
46. Pallis M., Turzanski J., Russell N.H. Blast maturity and CD34 expression determine the effects of the differentiating agents KH1060 and 9-cis-retinoic acid on the differentiation and clonogenicity of non-M3 acute myeloid leukemia cells. Leukemia. 12:1998;1741-1748.
47. Taimi M., Breitman T.R. N-4-hydroxyphenylretinamide enhances retinoic acid-induced differentiation and retinoylation of proteins in the human acute promyelocytic leukemia cell line, NB4, by a mechanism that may involve inhibition of retinoic acid catabolism. Biochem Biophys Res Commun. 232:1997;432-436.
48. Giandomenico V., Andreola F., Rodriguez de la Concepcion M.L., Collins S.J., De Luca L.M. Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells). Carcinogenesis. 20:1999;1133-1135.
49. Clifford J.L., Menter D.G., Wang M., Lotan R., Lippman S.M. Retinoid receptor-dependent and -independent effects of N-(4- hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 59:1999;14-18.
50. Darro F., Cahen P., Vianna A., et al. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat. 51:1998;39-55.
51. Moon R.C., Constantinou A.I. Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res Treat. 46:1997;181-189.
52. Abou-Issa H., Curley R.W. Jr, Panigot M.J., Tanagho S.N., Sidhu B.S., Alshafie G.A. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model. Anticancer Res. 17:1997;3335-3339.
53. Bednarek A., Shilkaitis A., Green A., et al. Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. Carcinogenesis. 20:1999;879-883.
54. Curley R.W. Jr, Abou-Issa H., Panigot M.J., Repa J.J., Clagett-Dame M., Alshafie G. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth. Anticancer Res. 16:1996;757-763.
55. Crist K.A., Wang Y., Lubet R.A., Steele V.E., Kelloff G.J., You M. Effect of early vs late administration of 4-hydroxyphenylretinamide (4- HPR) on N-methyl-N-nitrosourea (MNU)-induced mammary tumorigenesis. J Cell Biochem. 27:(Suppl):1997;92-99.
56. Rao G.N., Ney E., Herbert R.A. Effect of retinoid analogues on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treat. 48:1998;265-271.
57. Rodriguez-Burford C., Lubet R.A., Eto I., et al. Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model. Carcinogenesis. 20:1999;71-76.
58. Aboseif S.R., Dahiya R., Narayan P., Cunha G.R. Effect of retinoic acid on prostatic development. Prostate. 31:1997;161-167.
59. McCormick D.L., Rao K.V., Dooley L., et al. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res. 58:1998;3282-3288.
60. Tamura K., Nakae D., Horiguchi K., et al. Inhibition by N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid of exogenous and endogenous development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in the livers of rats. Carcinogenesis. 18:1997;2133-2141.
61. Zheng Y., Kramer P.M., Olson G., et al. Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis. 18:1997;2119-2125.
62. Zheng Y., Kramer P.M., Lubet R.A., Steele V.E., Kelloff G.J., Pereira M.A. Effect of retinoids on AOM-induced colon cancer in rats Modulation of cell proliferation, apoptosis and aberrant crypt foci . Carcinogenesis. 20:1999;255-260.
63. Conaway C.C., Jiao D., Kelloff G.J., Steele V.E., Rivenson A., Chung F.L. Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and beta-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Lett. 124:1998;85-93.
64. Chan L.N., Zhang S., Cloyd M., Chan T.S. N-(4-hydroxyphenyl)retinamide prevents development of T-lymphomas in AKR/J mice. Anticancer Res. 17:1997;499-503.
65. McCormick D.L., Johnson W.D., Rao K.V., et al. Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and alpha-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. Carcinogenesis. 17:1996;2513-2517.
66. Oridate N., Lotan D., Lotan R. Reconstituted basement membrane (Matrigel) A useful semisolid medium for anchorage-independent growth of tumor cells . In Vitro. 32:1996;248-251.
67. Pecoraro G., Morgan D., Defendi V. Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci U S A. 86:1989;563-567.
68. Formelli F., Clerici M., Campa T., et al. Five-year administration of fenretinide Pharmacokinetics and effects on plasma retinol concentrations . J Clin Oncol. 11:1993;2036-2042.
69. Anderson P., Koben J., Troutman W. Conversion factors. 9th ed:1999;Appleton & Lange, Stanford.
70. De Palo G., Camerini T., Marubini E., et al. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori. 83:1997;884-894.
71. Veronesi U., De Palo G., Marubini E., et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 91:1999;1847-1856.
72. Kurie J.M., Lee J.S., Khuri F.R., et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res. 6:2000;2973-2979.
73. Follen M., Atkinson E., Schottenfeld D., et al. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res. 7:2001;3356-3365.